Table 2.
HRs for Renal and Cardiovascular Outcomes by Categorical or Continuous Measure of OH
| OH | Unadjusted | Model 1 | Model 2 | Model 3 |
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |
| Primary outcome: eGFR decline ≥50% or chronic dialysis | ||||
| ≥7% vs <7% | 4.33 (2.69 to 6.97)* | 4.56 (2.83 to 7.36)* | 3.63 (2.20 to 5.99)* | 2.44 (1.44 to 4.13)† |
| 1 L increase | 1.29 (1.19 to 1.39)* | 1.34 (1.23 to 1.45)* | 1.26 (1.14 to 1.39)* | 1.25 (1.11 to 1.41)* |
| Secondary outcome: cardiovascular morbidity or mortality | ||||
| ≥7% vs <7% | 6.37 (2.85 to 14.23)* | 6.22 (2.78 to 13.92)* | 3.84 (1.68 to 8.76)† | 2.71 (1.14 to 6.48)† |
| 1 L increase | 1.28 (1.15 to 1.43)* | 1.42 (1.25 to 1.62)* | 1.28 (1.09 to 1.50)† | 1.25 (1.04 to 1.51)† |
Model 1 is adjusted for age and sex. Model 2 is adjusted for the model 1 variables and for cardiovascular disease, diabetes mellitus, systolic blood pressure, and the use of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. Model 3 is adjusted for the model 2 variables and for eGFR, and a urine protein–creatinine ratio cut-off value of 0.5. eGFR indicates estimated glomerular filtration rate; HR, hazard ratio; OH, overhydration.
*
P<0.001.
†
P<0.05.